AMBICION Co., Ltd. announced that it has completed raising funds from Regional Health Care Industry Support Fund and TOHO HOLDINGS CO., LTD. through third-party allocation of new shares.
With this capital increase, AMBICION accelerates its development programs of Natural Killer T (NKT) cell-targeted cancer therapy and the anti-allergy drugs.

Natural Killer T (NKT) cell

Natural Killer T (NKT) cells are unique T cells that combines the properties of NK cells. NKT cells were first discovered in 1986 by Dr. Masaru Taniguchi (currently Senior Visiting Scientist, RIKEN Cluster for Science, Technology and Innovation Hub, RIKEN Program for Drug Discovery and medical technology Platforms Clinical Development Support office) et al., and are known as the fourth lymphocyte following T, B cells, and NK cells. NKT cells account for around half of the T cells found in liver and bone marrow. NKT cells are activated promptly when glycolipid antigens are recognized. Multi-type cytokines are produced upon this activation, inducing both immune-stimulation and -suppression.

NKT cell-targeted anti-cancer therapy

NKT cell-targeted anti-cancer therapy aims to activate patient’s own NKT cells. First, patient’s mononuclear cells are collected by apheresis, first. Then targeted cells are isolated and cultivated with NKT cells activated ligands at Cell Processing Center. This cell product is administrated to the patient.